These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 24782424)

  • 1. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany.
    Pietzsch JB; Geisler BP; Garner AM; Zeller T; Jaff MR
    Catheter Cardiovasc Interv; 2014 Oct; 84(4):546-54. PubMed ID: 24782424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial.
    Salisbury AC; Li H; Vilain KR; Jaff MR; Schneider PA; Laird JR; Cohen DJ
    JACC Cardiovasc Interv; 2016 Nov; 9(22):2343-2352. PubMed ID: 27884360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK.
    Katsanos K; Geisler BP; Garner AM; Zayed H; Cleveland T; Pietzsch JB
    BMJ Open; 2016 May; 6(5):e011245. PubMed ID: 27160845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of paclitaxel-coated balloons for endovascular therapy of femoropopliteal arterial obstructions.
    Diehm N; Schneider H
    J Endovasc Ther; 2013 Dec; 20(6):819-25. PubMed ID: 24325699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of drug-eluting stents for the treatment of femoropopliteal disease provides significant cost-to-system savings in a single-state outpatient simulation.
    Sridharan ND; Liang N; Robinson D; Avgerinos E; Tzeng E; Makaroun MS; Chaer RA; Eslami MH
    J Vasc Surg; 2018 Nov; 68(5):1465-1472. PubMed ID: 29779962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery.
    Sridharan ND; Boitet A; Smith K; Noorbakhsh K; Avgerinos E; Eslami MH; Makaroun M; Chaer R
    J Vasc Surg; 2018 Jan; 67(1):343-352. PubMed ID: 28958476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
    Liistro F; Grotti S; Porto I; Angioli P; Ricci L; Ducci K; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1295-302. PubMed ID: 24239203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.
    Bonaventura K; Leber AW; Sohns C; Roser M; Boldt LH; Kleber FX; Haverkamp W; Dorenkamp M
    Clin Res Cardiol; 2012 Jul; 101(7):573-84. PubMed ID: 22350752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Plain Balloon Angioplasty, Bare Metal Stents, Drug-Coated Balloons, and Drug-Eluting Stents for the Treatment of Infrapopliteal Artery Disease: Systematic Review and Bayesian Network Meta-analysis of Randomized Controlled Trials.
    Katsanos K; Kitrou P; Spiliopoulos S; Diamantopoulos A; Karnabatidis D
    J Endovasc Ther; 2016 Dec; 23(6):851-863. PubMed ID: 27708143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic Drug Effect and Particulate Embolization of Drug-Eluting Stents versus Drug-Coated Balloons in Healthy Swine Femoropopliteal Arteries.
    Torii S; Yahagi K; Mori H; Harari E; Romero ME; Kolodgie FD; Young B; Ragheb A; Virmani R; Finn AV
    J Vasc Interv Radiol; 2018 Jul; 29(7):1041-1049.e3. PubMed ID: 29754850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angioplasty or bare metal stent versus drug-eluting endovascular treatment in femoropopliteal artery disease: a systematic review and meta-analysis.
    Varetto G; Gibello L; Boero M; Frola E; Peretti T; Spalla F; Verzini F; Rispoli P
    J Cardiovasc Surg (Torino); 2019 Oct; 60(5):546-556. PubMed ID: 31527577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions.
    Castro-Dominguez Y; Smolderen KG; Pichert M; Alabi O; Romain G; Huang J; Lee M; Ahmed Z; Peri-Okonny PA; Arham A; Brice A; Chaar CO; Stacy MR; Mena-Hurtado C
    J Vasc Surg; 2022 Dec; 76(6):1675-1680. PubMed ID: 35868423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?
    Antoniou GA; Georgakarakos EI; Antoniou SA; Georgiadis GS
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):282-5. PubMed ID: 24729201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAlloon versus Stenting in severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial.
    Hunt BD; Popplewell MA; Davies H; Meecham L; Jarrett H; Bate G; Grant M; Patel S; Hewitt C; Andronis L; Deeks JJ; Bradbury A;
    Trials; 2017 May; 18(1):224. PubMed ID: 28526046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angioplasty with drug coated balloons for the treatment of infrainguinal peripheral artery disease.
    Werner M
    Vasa; 2016 Sep; 45(5):365-72. PubMed ID: 27351416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Coated Balloon and Drug-Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease.
    Hanna J; Smolderen KG; Castro-Dominguez Y; Romain G; Lee M; Turner J; Mena-Hurtado C
    J Am Heart Assoc; 2023 Apr; 12(7):e028622. PubMed ID: 36974774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis.
    Dorenkamp M; Boldt J; Leber AW; Sohns C; Roser M; Boldt LH; Haverkamp W; Bonaventura K
    Clin Cardiol; 2013 Jul; 36(7):407-13. PubMed ID: 23595957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
    Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.